JPRN-UMIN000001821RecruitingPhase 1
Immunotherapy using WT1 peptide and a pertussis whole cell vaccine against recurrent prostate cancer: A phase I/II study - An immunotherapy against recurrent prostate cancer
Department of Immunology, Kochi University School of Medicine0 sites60 target enrollmentStarted: March 31, 2009Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Enrollment
- 60
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- Male
Inclusion Criteria
- Not provided
Exclusion Criteria
- •The following patients must be excluded: 1) Patients with uncontrollable infectious disease (including active Tuberculosis). 2) Patients with severe symptoms (malignant hypertension, severe congestive heart failure, severe colonary insufficiency, Myocardial Infarction within three months lately, terminal phase liver cirrhosis, uncontrollable Diabetes Mellitus, severe Pulmonary Fibrosis, active interstitial pneumonia, etc.). 3) Patients previously treated with Allogeneic bone marrow transplantation. 4) Patients with severe psychiatric disease. 5) Patients who participate in any other clinical trial. 6) Patients who previously participated in this clinical trial. 7) Any patients disqualified by a study physician because of medical, psychological, or any other factors.
Investigators
Similar Trials
Completed
Not Applicable
Immunotherapy using WT1 peptide and a pertussis whole cell vaccine against Head and Neck Tumor: A phase I/II studyHead and Neck TumorJPRN-UMIN000001906Anti-tumor Immunotherapy Research Network, Department of Immunology, Kochi Medical School65
Completed
Phase 1
Immunotherapy using WT1 peptide and a pertussis whole cell vaccine against malignant bone and soft tissue tumors: A phase I/II studyMalignant bone and soft tissue tumorsJPRN-UMIN000010257Department of Orthopaedic Surgery, Kochi Medical School20
Completed
Not Applicable
Immunotherapy using WT1 peptide against recurrent glioblastoma multiforme: A phase I/II study.glioblastoma multiformeJPRN-UMIN000002024Cancer Vaccination Therapy Research Network, Department of Immunology, Kochi Medical School30
Recruiting
Phase 1
Immunotherapy using WT1 peptide with surgical treatment, irradiation therapy, and Temozolomide administration against glioblastoma multiforme: A phase I/II study.glioblastoma multiformeJPRN-UMIN000002419Cancer Vaccination Therapy Research Network, Department of Immunology, Kochi Medical School45
Recruiting
Phase 1
W10TR-GBM2JPRN-jRCTs061180085eba Tetsuya90